MarketCap
Facebook
X
TelegramAnnual report 2025
added 02-24-2026
Iovance Biotherapeutics Total Assets 2011-2026 | IOVA
Total Assets — these are all the resources owned by the business that have economic value. They are used to operate the business, generate profit, and ensure the company’s stability.Main categories of assets
Current assets (used within one year):
- Cash and cash equivalents
- Accounts receivable (amounts owed by customers)
- Inventory of goods, raw materials, and supplies
- Short-term investments
- Fixed assets (buildings, machinery, equipment)
- Intangible assets (brands, patents, software)
- Long-term investments
- Goodwill (reputational value from mergers)
Assets represent an objective measure of a business's value, reflecting everything behind it: physical infrastructure, technology, customer base, and financial resources. A high share of liquid assets such as cash indicates a company’s financial flexibility and its ability to maintain stability in changing market conditions.
Asset analysis helps assess how effectively a company utilizes its resources to generate revenue and profit, reflecting its operational efficiency and ability to convert invested capital into financial results.
Annual Total Assets Iovance Biotherapeutics
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 913 M | 910 M | 780 M | 664 M | 777 M | 768 M | 345 M | 481 M | 155 M | 172 M | 106 M | 46.5 M | 19.9 M | 29.4 K | 568 K |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 913 M | 29.4 K | 409 M |
Quarterly Total Assets Iovance Biotherapeutics
| 2025-Q3 | 2025-Q2 | 2025-Q1 | 2024-Q4 | 2024-Q3 | 2024-Q2 | 2024-Q1 | 2023-Q4 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 905 M | 907 M | 967 M | 910 M | 991 M | 964 M | 870 M | 780 M | 852 M | 757 M | 825 M | 664 M | 546 M | - | 701 M | 777 M | 829 M | 853 M | 751 M | 768 M | 768 M | 768 M | 768 M | 345 M | 345 M | 345 M | 345 M | 481 M | 481 M | 481 M | 481 M | 155 M | 155 M | 155 M | 155 M | 172 M | 172 M | 172 M | 172 M | 106 M | 106 M | 106 M | 106 M | 46.5 M | 46.5 M | 46.5 M | 46.5 M | 19.9 M | 19.9 M | 19.9 M | 19.9 M | 29.4 K | 29.4 K | 29.4 K | 29.4 K | 568 K | 568 K | 568 K | 568 K |
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| 991 M | 29.4 K | 400 M |
Total Assets of other stocks in the Biotechnology industry
| Issuer | Total Assets | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
 |
MorphoSys AG
MOR
|
2.03 B | - | 2.43 % | $ 254 M |  Germany |
 |
AgeX Therapeutics
AGE
|
6.95 M | - | -10.17 % | $ 12.2 K |  USA |
 |
I-Mab
IMAB
|
6.33 B | - | - | $ 866 M |  China |
 |
Midatech Pharma plc
MTP
|
18.2 M | - | -18.52 % | $ 27.3 M |  Britain |
 |
Alexion Pharmaceuticals, Inc.
ALXN
|
18.1 B | - | - | $ 40.3 B | USA |
 |
Biophytis SA
BPTS
|
12 M | - | -13.47 % | $ 169 M |  France |
 |
Genfit SA
GNFT
|
151 M | - | 2.54 % | $ 160 B | France |
 |
EyeGate Pharmaceuticals, Inc.
EYEG
|
15.2 M | - | -1.52 % | $ 24.7 M | USA |
 |
Athira Pharma
ATHA
|
92.2 M | - | - | $ 269 M | USA |
 |
BioNTech SE
BNTX
|
22 B | $ 95.13 | -0.38 % | $ 27.2 B | Germany |
 |
Институт стволовых клеток человека
ISKJ
|
1.51 B | - | - | - |  Russia |
 |
Checkmate Pharmaceuticals
CMPI
|
78.8 M | - | - | $ 231 M | USA |
 |
INmune Bio
INMB
|
32.4 M | $ 1.55 | 0.65 % | $ 38.4 M | USA |
 |
ACADIA Pharmaceuticals
ACAD
|
1.19 B | $ 22.82 | 2.1 % | $ 3.78 B | USA |
 |
Advaxis
ADXS
|
16.6 M | - | -9.65 % | $ 45.9 M | USA |
 |
Can-Fite BioPharma Ltd.
CANF
|
9.51 M | $ 3.51 | 0.29 % | $ 5.78 M |  Israel |
 |
Aeterna Zentaris
AEZS
|
21.4 M | - | 5.93 % | $ 314 M |  Canada |
 |
Aeglea BioTherapeutics
AGLE
|
778 M | - | - | $ 1.01 B | USA |
 |
CureVac N.V.
CVAC
|
1.16 B | - | - | $ 867 M | Germany |
 |
Applied Genetic Technologies Corporation
AGTC
|
66.7 M | - | - | $ 26.5 M | USA |
 |
AIkido Pharma
AIKI
|
113 M | - | 1.93 % | $ 17.4 M | USA |
 |
Akero Therapeutics
AKRO
|
826 M | - | - | $ 3.67 B | USA |
 |
Aptose Biosciences
APTO
|
10 M | - | -45.71 % | $ 1.2 M | Canada |
 |
Aptinyx
APTX
|
66.7 M | - | -39.0 % | $ 4.57 M | USA |
 |
Akouos
AKUS
|
279 M | - | 0.23 % | $ 488 M | USA |
 |
Albireo Pharma
ALBO
|
302 M | - | -0.23 % | $ 916 M | USA |
 |
Allakos
ALLK
|
244 M | - | - | $ 28.6 M | USA |
 |
AlloVir
ALVR
|
122 M | - | 4.14 % | $ 49.1 M | USA |
 |
Arcutis Biotherapeutics
ARQT
|
433 M | $ 23.4 | -0.09 % | $ 2.98 B | USA |
 |
Nanobiotix S.A.
NBTX
|
67.8 M | $ 41.5 | 19.36 % | $ 286 B | France |
 |
Allena Pharmaceuticals
ALNA
|
34.8 M | - | 3.16 % | $ 1.9 M | USA |
 |
Ampio Pharmaceuticals
AMPE
|
5.74 M | - | -11.43 % | $ 502 K | USA |
 |
Applied Molecular Transport
AMTI
|
107 M | - | - | $ 10.1 M | USA |
 |
Alpine Immune Sciences
ALPN
|
287 M | - | - | $ 2.17 B | USA |
 |
Aileron Therapeutics
ALRN
|
24.2 M | - | 10.36 % | $ 9.8 M | USA |
 |
Applied Therapeutics
APLT
|
54.8 M | - | - | $ 8.42 M | USA |
 |
Aravive
ARAV
|
62.2 M | - | -13.39 % | $ 1.45 M | USA |
 |
Aridis Pharmaceuticals
ARDS
|
14.7 M | - | 17.91 % | $ 11.1 M | USA |
 |
CRISPR Therapeutics AG
CRSP
|
2.27 B | $ 53.41 | 1.97 % | $ 4.8 B |  Schweiz |
 |
Avenue Therapeutics
ATXI
|
2.93 M | - | -52.27 % | $ 4.45 M | USA |
 |
Autolus Therapeutics plc
AUTL
|
589 M | $ 1.68 | 2.44 % | $ 447 M | Britain |
 |
AVROBIO
AVRO
|
101 M | - | 1083.1 % | $ 745 M | USA |
 |
Ayala Pharmaceuticals
AYLA
|
7.77 M | - | - | $ 7.46 M | Israel |
 |
Завод ДИОД
DIOD
|
1.4 B | - | - | - | Russia |
 |
Фармсинтез
LIFE
|
2.05 B | - | - | - | Russia |
 |
AstraZeneca PLC
AZN
|
114 B | - | - | $ 96.9 B | Britain |
 |
Atreca
BCEL
|
155 M | - | -11.76 % | $ 5.79 M | USA |
 |
Brainstorm Cell Therapeutics
BCLI
|
1.02 M | - | -2.5 % | $ 5.88 M | USA |
 |
BioDelivery Sciences International
BDSI
|
325 M | - | -4.8 % | $ 255 M | USA |
 |
BeiGene, Ltd.
BGNE
|
8.19 B | - | 0.49 % | $ 251 B |  Cayman-islands |